Treatment with biologics in chronic plaque psoriasis—consensus statements and recommendations from the dermatological society of Kuwait
Open Access
- 2 December 2025
- journal article
- practice guideline
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2588071
Abstract
Introduction: Psoriasis is a chronic disease. Its management is based on disease severity, clinical implications, and patients' quality of life. Biological agents are available in Kuwait for the treatment of moderate-to-severe chronic psoriasis and are frequently used. The Kuwait Society of Dermatologists decided to develop consensus statements and recommendations for the use of biologics in moderate-to-severe plaque psoriasis in Kuwait. This paper reports these consensus statements. Methods: An advisory board composed of psoriasis experts was formed, and a robust literature review was conducted. After several deliberations, experts proposed a few statements for further deliberations and refinement. The finalized consensus statements were put to a vote by the experts. The maximum rating was 10, and an average rating above 8 was considered to meet the << acceptance criteria>> for the proposed statement and recommendations. Results: A total of seventeen consensus statements were formulated. They were grouped under eight specific domains. The average rating for the consensus statements ranged from 8.9 to 9.8, and all statements were accepted. Conclusions: The consensus statements aim to systematically and holistically treat patients with plaque psoriasis in Kuwait using biologics while caring for their overall health, comorbidities, and mental health. These consensus statements are developed after rigorous deliberation, a review of international guidelines, and the clinical practice followed in Kuwait to guide the systematic and standardised use of biologics for plaque psoriasis.Keywords
Funding Information
- Johnson & Johnson and AbbVie
This publication has 54 references indexed in Scilit:
- Management of Psoriasis Patients with Serious Infectious DiseasesAdvances in Therapy, 2024
- Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health RecordsJAMA Dermatology, 2022
- Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysisClinical and Experimental Medicine, 2022
- Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation SurveyAdvances in Therapy, 2022
- Association Between Biologics Use and Risk of Serious Infection in Patients With PsoriasisJAMA Dermatology, 2021
- Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic ReviewDermatology and Therapy, 2021
- Psychological Therapies in Management of Psoriatic Skin Disease: A Systematic ReviewAmerican Journal of Clinical Dermatology, 2019
- Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic ReviewAmerican Journal of Clinical Dermatology, 2019
- Risk of Serious Infection With Biologic and Systemic Treatment of PsoriasisJAMA Dermatology, 2015
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011